South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
The Maire - EuroChem Case: Three Lessons for Global Business 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Gold Prices Smash Record Above $5,200 as Haven Demand Surges 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Indonesian Stocks Slide After MSCI Flags Investability Risks and Downgrade Threat 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
U.S. Stock Index Futures Steady as Fed Decision and Big Tech Earnings Loom 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Thailand Moves to Regulate Gold Trading to Curb Baht Strength and Support Economic Growth 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
China to Boost Brazilian Soybean Imports in Early 2026 Amid Price Advantage 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
